Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth H Stover

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Methods in Molecular Medicine|March 1, 2006
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemiaJan Cools, Elizabeth H Stover, D Gary Gilliland
Molecular Plant-Microbe Interactions : MPMI|March 26, 2003
The HrpX/HrpY two-component system activates hrpS expression, the first step in the regulatory cascade controlling the Hrp regulon in Pantoea stewartii subsp. stewartiiMassimo Merighi, Doris R Majerczak, Elizabeth H Stover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
Biomarkers of Response and Resistance to DNA Repair Targeted TherapiesElizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, et al.
Current Opinion in Hematology|December 17, 2003
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaJan Cools, Elizabeth H Stover, Iwona Wlodarska, et al.
Gynecologic Oncology|October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiencyElizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Cancer Investigation|July 7, 2007
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomideAbraham B Schwarzberg, Elizabeth H Stover, Tanya Sengupta, et al.
Gynecologic Oncology|July 18, 2025
The RAS-MEK-ERK pathway in low-grade serous ovarian cancerElizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, et al.
International Journal of Molecular Sciences|November 21, 2020
Genomic Amplification and Functional Dependency of the Gamma Actin Gene <i>ACTG1</i> in Uterine CancerCamden Richter, David Mayhew, Jonathan P Rennhack, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2006
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentElizabeth H Stover, Jing Chen, Cedric Folens, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Methods in Molecular Medicine|March 1, 2006
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemiaJan Cools, Elizabeth H Stover, D Gary Gilliland
Molecular Plant-Microbe Interactions : MPMI|March 26, 2003
The HrpX/HrpY two-component system activates hrpS expression, the first step in the regulatory cascade controlling the Hrp regulon in Pantoea stewartii subsp. stewartiiMassimo Merighi, Doris R Majerczak, Elizabeth H Stover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
Biomarkers of Response and Resistance to DNA Repair Targeted TherapiesElizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, et al.
Current Opinion in Hematology|December 17, 2003
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaJan Cools, Elizabeth H Stover, Iwona Wlodarska, et al.
Gynecologic Oncology|October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiencyElizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Cancer Investigation|July 7, 2007
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomideAbraham B Schwarzberg, Elizabeth H Stover, Tanya Sengupta, et al.
Gynecologic Oncology|July 18, 2025
The RAS-MEK-ERK pathway in low-grade serous ovarian cancerElizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, et al.
International Journal of Molecular Sciences|November 21, 2020
Genomic Amplification and Functional Dependency of the Gamma Actin Gene <i>ACTG1</i> in Uterine CancerCamden Richter, David Mayhew, Jonathan P Rennhack, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2006
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentElizabeth H Stover, Jing Chen, Cedric Folens, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Pageof 4